PAA 4.88% 21.5¢ pharmaust limited

Ann: Research Collaboration & Joint Patent with Japanese Company, page-16

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 613 Posts.
    lightbulb Created with Sketch. 180
    It's right there on the first page of that report.

    New Patent Filing – PPL1 Mystery Revealed Through our investigation we discovered that Pitney has recently published a patent on the use of monepantel (an aminoacetonitrile derivative) for the treatment of cancer (Source: http://patentscope.wipo.int/search/en/WO2013138863). Aminoacetonitrile derivatives (AADs) are a class of anthelmintics effective against drug-resistant nematodes. Although PAA has not confirmed our investigations, it appears that the only marketed monepantel product is Zolvix®, produced and distributed by Novartis Animal Health (Source: http://zolvix.com/monepantel/). Recall that PAA’s disclosed lead product is an anthelminthic which is being targeted to the treatment of both veterinary and human cancers.
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
21.5¢
Change
0.010(4.88%)
Mkt cap ! $104.6M
Open High Low Value Volume
20.5¢ 21.5¢ 20.5¢ $244.1K 1.163M

Buyers (Bids)

No. Vol. Price($)
3 71981 21.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.5¢ 84173 3
View Market Depth
Last trade - 16.10pm 11/10/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.